According to CoinMeta, it was learned from the National Healthcare Security Administration that in 2026, the national medical insurance drug list and the commercial health insurance innovative drug list were released in Suzhou. The new version of the national medical insurance drug list includes 107 additional drugs, among which 51 are new category 1 drugs, setting a new historical high. The newly added varieties cover multiple areas that are urgently in need of clinical treatment, such as tumors, rare diseases, chronic diseases, and mental illnesses. The adjustment of the commercial health insurance innovative drug list was carried out simultaneously, with 12 new drugs added, including the world's first CAR-T for solid tumors and China's first gene therapy drug for hemophilia, among other major innovative medications. After the adjustment, there are now 28 drugs in the 2026 commercial health insurance innovative drug list. With this adjustment, the total number of drugs in the 2026 national medical insurance drug list reaches 3,331, with 1,935 being Western medicines and 1,396 being traditional Chinese medicines. The new list will officially come into effect on January 1, 2027. (Xinhua News Agency)